New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePT-141 (Bremelanotide) vs DS5

PT-141 (Bremelanotide) vs DS5

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
PT-141 (Bremelanotide)
Sleep Optimization
DS5
Summary
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist that enhances sexual desire and arousal through central nervous system mechanisms. It is FDA-approved as Vyleesi for premenopausal women with hypoactive sexual desire disorder (HSDD).
DS5 is a synthetic variant of the delta sleep-inducing peptide (DSIP), a nonapeptide originally isolated from rabbit cerebrospinal fluid during slow-wave sleep. Like DSIP, DS5 is explored for sleep optimization, stress modulation, and circadian rhythm normalization, with proposed improvements in potency or stability over the parent molecule.
Half-Life
2–3 hours
Estimated 30-60 minutes (peptide degradation)
Admin Route
SubQ
Subcutaneous, Intranasal (research)
Research
Typical Dose
0.5–1.75 mg
200-500 mcg per dose
Frequency
As needed (not daily)
Once nightly
Key Benefits
  • Enhances sexual desire and libido in both men and women
  • Improves arousal through central nervous system activation
  • Effective for psychological erectile dysfunction
  • Works for female sexual arousal disorder
  • May improve sexual satisfaction and intensity
  • Fast-acting — effects within 45–60 minutes
  • FDA-approved for HSDD in premenopausal women
  • Promotes delta-wave (deep) sleep and improves sleep quality
  • May reduce sleep onset latency
  • HPA axis modulation for stress reduction
  • Non-addictive sleep support without tolerance development
  • Potential circadian rhythm normalization
  • Explored for insomnia, chronic stress, and PTSD-related sleep disturbance
Side Effects
  • Nausea (most common — 40% of users in clinical trials)
  • Facial flushing and warmth
  • Transient blood pressure changes (typically increase then normalize)
  • Headache
  • +2 more
  • Generally well-tolerated in research subjects
  • Possible morning grogginess at higher doses
  • Mild blood pressure fluctuations reported with DSIP
  • Limited human safety data for DS5 specifically
Stacks With